A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies
Simple Summary Platinum-resistant ovarian cancer (PROC) is no longer managed only with sequential single-agent chemotherapy. Randomized phase III trials now support pembrolizumab plus weekly paclitaxel with or without bevacizumab, mirvetuximab soravtansine for FRα-high disease, and relacorilant plus nab-paclitaxel, whi...